Literature DB >> 16389265

Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.

I Mertens1, A Verrijken, J J Michiels, M Van der Planken, J B Ruige, L F Van Gaal.   

Abstract

OBJECTIVE: To investigate whether leukocyte count, fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 activity (PAI-1) are increased in subjects with the metabolic syndrome as defined by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) and the World Health Organisation (WHO).
DESIGN: Cross-sectional study.
SUBJECTS: A total of 520 overweight and obese subjects: 379 women and 141 men, visiting the weight management clinic of a University Hospital. SUBJECTS AND MEASUREMENTS: Waist circumference, triglycerides, HDL cholesterol, blood pressure and fasting glucose were determined, and the presence or absence of the metabolic syndrome according to the NCEP-ATPIII criteria was assessed. In 349 subjects, data on the waist-to-hip ratio (WHR) and albumin excretion rate were available and the WHO criteria were applied. Insulin resistance was defined using the HOMA-IR index.
RESULTS: Subjects with the metabolic syndrome according to the NCEP-ATPIII criteria had significantly higher levels of leukocyte count (P < 0.001) and PAI-1 (P < 0.001), while no significant differences were found for fibrinogen or vWF (P > 0.05). Using the WHO criteria, similar results were found except for vWF, where higher levels were found in subjects with the metabolic syndrome. When subjects were classified according to the number of components of the metabolic syndrome, levels of leukocyte count, vWF and PAI-1 activity were significantly different (P < 0.05). In logistic regression analysis PAI-1, gender and leukocyte count were independent determinants of the metabolic syndrome (P < 0.001).
CONCLUSION: Evidence for being a true component of the metabolic syndrome is strong for PAI-1, less for leukocyte count and weak for vWF and fibrinogen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389265     DOI: 10.1038/sj.ijo.0803189

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  49 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

2.  Insulin resistance explains the relationship between novel cardiovascular risk factors and hypertension. The Telde Study.

Authors:  A M Wägner; J C Wiebe; M Boronat; P Saavedra; D Marrero; F Varillas; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

3.  Metabolic effects of obesity: A review.

Authors:  Parul Singla; Animesh Bardoloi; Anuj A Parkash
Journal:  World J Diabetes       Date:  2010-07-15

4.  Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Authors:  Anna K Kopec; Sara R Abrahams; Sherry Thornton; Joseph S Palumbo; Eric S Mullins; Senad Divanovic; Hartmut Weiler; A Phillip Owens; Nigel Mackman; Ashley Goss; Joanne van Ryn; James P Luyendyk; Matthew J Flick
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 5.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

6.  Consuming a balanced high fat diet for 16 weeks improves body composition, inflammation and vascular function parameters in obese premenopausal women.

Authors:  Heidi J Silver; Hakmook Kang; Charles D Keil; James A Muldowney; Heidi Kocalis; Sergio Fazio; Douglas E Vaughan; Kevin D Niswender
Journal:  Metabolism       Date:  2014-01-17       Impact factor: 8.694

7.  Myeloid-specific deletion of thrombospondin 1 protects against inflammation and insulin resistance in long-term diet-induced obese male mice.

Authors:  Hasiyet Memetimin; Dong Li; Kaiyuan Tan; Changcheng Zhou; Ying Liang; Yadi Wu; Shuxia Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-23       Impact factor: 4.310

Review 8.  Adipocytokines and the metabolic complications of obesity.

Authors:  Neda Rasouli; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

9.  Increased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based Study.

Authors:  Anne Huotari; Soili M Lehto; Leo Niskanen; Karl-Heinz Herzig; Jukka Hintikka; Heli Koivumaa-Honkanen; Tommi Tolmunen; Kirsi Honkalampi; Noora Kaikkonen; Heimo Viinamäki
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-03-14

10.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.